Amorphous Solid Dispersion Hydrogel Platform for Transdermal Delivery of Cannabidiol with Therapeutic Potential for Dermatitis
Pharmaceutics · 28.05.2026 · 18 (6) · 666
DOI: 10.3390/pharmaceutics18060666 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 28.05.2026. Verfasst von Badmaarag-Altai Chuluunbaatar und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jeonbuk National University, Jeonju 54896, Republic of Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of the Republic of Korea, Ministry of Education, Korean government.
Abstract (Originalsprache)
Background/Objectives: Cannabis sativa is the source of cannabidiol (CBD), a non-intoxicating phytocannabinoid with analgesic and anti-inflammatory qualities that has demonstrated therapeutic potential in inflammatory skin conditions like dermatitis. However, low bioavailability and poor water solubility restrict its topical application. This study attempted to improve CBD solubility and transdermal delivery using an amorphous solid dispersion (ASD)-based hydrogel system.
Methods
CBD was stabilized in its amorphous form using an ASD strategy and incorporated into a hydrogel matrix. The CBD-ASD hydrogel was characterized by particle size analysis, scanning electron microscopy (SEM), Fourier-transform infrared spectroscopy (FT-IR), rheological assessment, swelling studies, and diffusion experiments using Franz cells. Biological evaluations included cytotoxicity testing in human dermal fibroblast (HDF) cells, wound-healing assays, RT-qPCR-based anti-inflammatory analysis, antioxidant activity (DPPH assay), and antibacterial testing against Staphylococcus aureus.
Results
Physicochemical analyses confirmed successful amorphous dispersion of CBD within a stable hydrogel network. The formulation exhibited sustained drug release over 144 h, achieving 86.32% cumulative release with diffusion-controlled kinetics. Rheological and swelling properties demonstrated mechanical stability and hydration suitability for long-term topical application, while Franz diffusion studies confirmed effective transdermal permeation. The CBD-ASD hydrogel showed no cytotoxicity in HDF cells and significantly enhanced wound closure. It also downregulated pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Additionally, the formulation demonstrated 65.63 ± 10.00% DPPH radical scavenging activity and over 99% antibacterial inhibition.
Conclusions
The CBD-ASD hydrogel represents a stable, multifunctional delivery platform that overcomes CBD solubility limitations and enhances therapeutic efficacy for inflammatory skin diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Jeonbuk National University, Jeonju 54896, Republic of Korea.
- Department of Bionanotechnology and Bioconvergence Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea.
- Institute of New Drug Development, Jeonbuk National University, Jeonju 54928, Republic of Korea.
- Respiratory Drug Development Research Institute, Jeonbuk National University, Jeonju 54928, Republic of Korea.
- College of Pharmacy, Woosuk University, Wanju 55338, Republic of Korea.
- Research Institute of Pharmaceutical Sciences, Woosuk University, Wanju 55338, Republic of Korea.
ORCID-Profile: Jae Woon Son, Ji-Hyun Kang, Kyung Hyun Min
Förderung
- Government of the Republic of Korea
- Ministry of Education
- Korean government
- Ministry of Education (MOE) and Jeonbuk State, Republic of Korea
Zitieren
APA
Chuluunbaatar, B. A., Jeong, Y., Ok, J., Song, Y., Son, J. W., Kang, J. H., Lee, W., & Min, K. H. (2026). Amorphous Solid Dispersion Hydrogel Platform for Transdermal Delivery of Cannabidiol with Therapeutic Potential for Dermatitis. Pharmaceutics, 18(6), 666. https://doi.org/10.3390/pharmaceutics18060666
Vancouver
Chuluunbaatar BA, Jeong Y, Ok J, Song Y, Son JW, Kang JH, et al. Amorphous Solid Dispersion Hydrogel Platform for Transdermal Delivery of Cannabidiol with Therapeutic Potential for Dermatitis. Pharmaceutics. 2026;18(6):666. doi:10.3390/pharmaceutics18060666
BibTeX
@article{Chuluunbaatar2026,
author = {Chuluunbaatar, Badmaarag-Altai and Jeong, Yujin and Ok, Jieun and Song, Yujin and Son, Jae Woon and Kang, Ji-Hyun and Lee, Wonwoong and Min, Kyung Hyun},
title = {Amorphous Solid Dispersion Hydrogel Platform for Transdermal Delivery of Cannabidiol with Therapeutic Potential for Dermatitis},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {6},
pages = {666},
doi = {10.3390/pharmaceutics18060666}
}
EUVIMED